^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAPK12 (Mitogen-Activated Protein Kinase 12)

    i
    Other names: MAPK12, Mitogen-Activated Protein Kinase 12, ERK6, PRKM12, SAPK-3, SAPK3, Mitogen-Activated Protein Kinase P38 Gamma, Extracellular Signal-Regulated Kinase 6, Stress-Activated Protein Kinase 3, MAP Kinase P38 Gamma, MAP Kinase 12, P38gamma, MAPK 12, ERK-6, Mitogen-Activated Protein Kinase 3, P38GAMMA, ERK3
    Associations

    News

    Trials
    2ms
    Identification of MAPK12 as a Prognostic Biomarker for Esophageal Carcinoma Using Bioinformatics and Machine Learning. (PubMed, Biomed Res Int)
    The model robustly predicted survival of patients with ESCA, supported by both high-throughput data and experimental evidence. Our findings highlight MAPK12 as a promising biomarker and provide a theoretical basis for understanding ESCA pathogenesis and developing targeted therapies.
    Journal
    |
    MAPK12 (Mitogen-Activated Protein Kinase 12)
    4ms
    Investigating the Roles of MAPKs as Precision Oncology Targets: A Multi-cancer Expression and Survival Study. (PubMed, Cancer Genomics Proteomics)
    Our integrated approach underscores the value of MAPK family members as both biomarkers and therapeutic targets in LIHC and LUAD. This study contributes important insights into MAPK-related oncogenic processes and supports the development of targeted therapies under the framework of precision oncology.
    Journal
    |
    MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK9 (Mitogen-Activated Protein Kinase 9) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    5ms
    Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. (PubMed, Cell Rep Med)
    Inhibiting the DDR1/2-MAPK12-GLI axis enhances the effectiveness of chemotherapy and immunotherapy in patient tumor slices and preclinical models. These findings highlight the importance of DDR1/2-MAPK12-GLI axis in CAF function and demonstrate the utility of 3D tissue models in identifying microenvironment-specific therapeutic targets.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    5ms
    The KRAS-G12D mutation drives venous thromboembolism (VTE) and colorectal cancer progression via MAPK/ERK signaling. (PubMed, Transl Oncol)
    Our findings establish KMCG as a novel biomarker integrating thrombotic risk and tumor progression, while mechanistically linking KRAS-G12D-driven MAPK activation to both cancer metastasis and thrombosis. This dual regulatory axis provides therapeutic targets for simultaneously managing thrombotic complications and malignant progression in KRAS-mutant CRC.
    Journal • Tumor mutational burden • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • PLCG2 (Phospholipase C Gamma 2) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    6ms
    The Role of MAPK12 in Prognosis of Patients With Liver Cancer and Effects on Stemness Characteristics. (PubMed, Stem Cells Int)
    Through the use of the SwissTargetPrediction tool, we precisely identified molecular targets related to Sorafenib...The results of in vitro experiments demonstrated that knockdown of MAPK12 reduced the proliferation, metastasis, and tumor stemness-related sphere-forming ability of LIHC cells. These results underscore the promise of MAPK12 as a potential prognostic biomarker for LIHC and offer valuable insights for crafting personalized treatment approaches.
    Journal
    |
    MAPK12 (Mitogen-Activated Protein Kinase 12)
    |
    sorafenib
    7ms
    Investigation of novel nimesulide derivatives against breast cancer. (PubMed, Bioorg Chem)
    Western blot results showed a dose-dependent decrease in p-ERK levels in both MCF-7 and MDA-MB-231 cells, confirming MAPK pathway inhibition. These findings support that nimesulide-based semicarbazones, particularly compound 5e, exhibit potent antiproliferative and pro-apoptotic activity via MAPK pathway modulation, offering a promising avenue for the development of targeted breast cancer therapies.
    Journal
    |
    ANXA5 (Annexin A5) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    7ms
    Long Term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model. (PubMed, J Clin Endocrinol Metab)
    This model identifies mutated genes that are associated with the most aggressive ATCs and thus may aid in preoperative risk assessment when evaluating patients for surgery for curative intent.
    Journal
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MUC4 (Mucin 4, Cell Surface Associated) • RECQL4( RecQ Like Helicase 4) • ZMYND8 (Zinc Finger MYND-Type Containing 8) • FLNC (Filamin C) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    9ms
    CD47 Expression in Classic Follicular Lymphoma is Associated with Event-Free Survival. (PubMed, Hum Pathol)
    Validation in larger case cohorts is required to further support the potential application of CD47-targeted approaches in patients with FL and to explore novel therapeutic strategies. In addition, differentially expressed genes in CD47-high versus CD47-low expressors raises potential areas of interest for further study.
    Journal
    |
    CD47 (CD47 Molecule) • CCND2 (Cyclin D2) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    1year
    Activation of P38 MAPK Signaling Cascade is Linked with Clinical Outcomes and Therapeutic Responses in Human Cancers. (PubMed, Biochemistry (Mosc))
    For instance, higher activation of the p38β and p38γ pathways was linked to positive responses to taxane and anthracycline therapies in breast cancer, while lower activation of the p38α and p38β pathways correlated with better responses to 5-fluorouracil-based treatments in colorectal cancer. However, associations with individual MAPK14, MAPK11, MAPK12, and MAPK13 gene expression levels were less robust. Hence, the p38 pathway activation levels could serve as potential biomarkers for predicting clinical outcomes and personalizing treatment strategies, including use of the selective p38 MAPK inhibitors.
    Clinical data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14)
    |
    5-fluorouracil
    1year
    Three-dimensional genome architecture in intrahepatic cholangiocarcinoma. (PubMed, Cell Oncol (Dordr))
    This study reveals relationship between 3D genome structural variations and gene dysregulation during ICC tumorigenesis, indicating the molecular mechanisms and potential biomarkers.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • ACVR1 (Activin A Receptor Type 1) • F13B (Coagulation Factor XIII B Chain) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    over1year
    In silico exploration of phytochemicals as inhibitors for acute myeloid leukemia by targeting LIN28A gene: A cheminformatics study. (PubMed, Comput Biol Med)
    This study elucidated that baicalein, 18β-glycyrrhizic, and limonin may be applied as potential candidates for targeting Lin28A as an active oncogene for acute myeloid leukemia.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MAPK12 (Mitogen-Activated Protein Kinase 12)
    over1year
    Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. (PubMed, J Clin Exp Hematop)
    Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.
    Journal
    |
    JAK2 (Janus kinase 2) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MAPK1 (Mitogen-activated protein kinase 1) • VEGFC (Vascular Endothelial Growth Factor C) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL18BP (Interleukin 18 Binding Protein) • IL1R1 (Interleukin 1 receptor, type I) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • NFKBIA (NFKB Inhibitor Alpha 2) • STAT2 (Signal transducer and activator of transcription 2) • IL3 (Interleukin 3) • IL33 (Interleukin 33) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9) • PDGFC (Platelet Derived Growth Factor C) • TNFAIP8 (TNF Alpha Induced Protein 8) • MAPK10 (Mitogen-Activated Protein Kinase 10)